| Hans-Günter Meyer-Thompson | Buprenorphin
Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction
– Head-to-head study of CAM2038 versus daily sublingual buprenorphine
– CAM2038 met both FDA and EMA primary endpoints of non-inferiority (p<0.001)
– CAM2038 demonstrated statistical superiority for the key secondary endpoint (p=0.004)
– Robust clinical data to support MAA and NDA submissions in mid-2017
– The CAM2038 development program targets an urgent and growing opioid crisis in the U.S. and globally
(Press release, Princeton, New Jersey and Lund, Sweden, 14.11.2016)